Skip to main content
. 2020 Feb 29;1221:493–522. doi: 10.1007/978-3-030-34521-1_20

Table 20.1.

Comparison of physical and biological properties of RO-N desulfated heparins

Code description % gs/monomers Mw kDa Anti-Heparanase activity IC50 ng/mL In vivo % CAG tumor inhibition∗
G8340 RO-N-desulfated heparin 62 8.4 20 75
G8438 RO-N-desulfated heparin 44 6.8 60 n.d.
G9578 RO-N-desulfated heparin 47 6.3 75 63
G4000 Roneparstat 25 16.0 3 62

∗in vivo human CAG multiple myeloma growth inhibition after 14 days treatment with drugs administered at 60 mg/Kg/day by subcutaneous continuous delivery [128]